• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

May 22, 2015

View Archived Issues

Skin in the game: Argen-x, Leo in $116M MAb dermatology pact

DUBLIN – Argen-x NV and Leo Pharma A/S entered an alliance, potentially worth more than €104.5 million (US$116 million) on the development of antibody drugs for inflammatory skin conditions, in a move that marks Leo's first foray into biologic drug development. Read More

Bill 'Cures' partisanship in House committee love fest with 51-0 vote

In a self-declared "love fest," the House Energy and Commerce Committee put aside partisan politics Thursday, voting 51-0 to pass the 21st Century Cures Act, H.R. 6, in the hope of streamlining the process of developing and approving new medical treatments. Read More

Cures bill allocates $550M for FDA; agency indicates it may need $958M

The 21st Century Cures Act may eventually set a new legislative land speed record for conception to passage in the House of Representatives, but the bill nonetheless reintroduces interested parties to an issue as old as budgets themselves. The bill would forward roughly $550 million to the FDA for its share of the Cures lift, but the agency estimates that its share of the work might cost a bit more than $958 million, leaving the FDA with a $400 million-plus hole to fill should the bill be signed into law. Read More

China's drug price cap removal likely to benefit larger pharmas: analyst

HONG KONG – Following the National Development and Reform Commission (NDRC)'s notice on removing the government price cap on most of the drugs in China, the government is slowly but gradually loosening its grip on drug prices. Large domestic pharmaceutical firms are most likely to benefit from that deregulation. Read More

WGS helps those sequenced, and possibly others, get a diagnosis

LONDON – The largest such study to date has demonstrated whole genome sequencing can be applied to the routine clinical diagnosis of rare inherited disorders for which there are currently no standard genetic tests. Read More

Holiday Notice

BioWorld's offices will be closed Monday, May 25 in observance of the Memorial Day holiday in the U.S. Read More

Regulatory front

Greater transparency is needed in biosimilar labeling than what the FDA approved for Sandoz Inc.'s Zarxio (filgrastim-sndz), according to eight organizations representing physicians who routinely prescribe biologics. Read More

Financings

Dicerna Pharmaceuticals Inc., of Cambridge, Mass., priced an underwritten registered public offering of 2.75 million common shares (NASDAQ:DRNA) at $17.75 apiece, expecting to raise $48.8 million, and granted underwriters a 30-day option to purchase up to 412,500 additional common shares, potentially generating another $7.3 million. Read More

Stock movers

Read More

Other news to note

Intellipharmaceutics International Inc., of Toronto, said the FDA provided notification stating the company will not be required to conduct phase III studies of Rexista, its abuse-deterrent version of oxycodone hydrochloride, if bioequivalence to Oxycontin is demonstrated. Read More

Appointments and advancements

Ziopharm Oncology Inc., of Boston, appointed Laurence J. N. Cooper CEO. Read More

In the clinic

Cytrx Corp., of Los Angeles, said updated data from an ongoing open-label phase II trial of aldoxorubicin for the treatment of unresectable glioblastoma multiforme (GBM) suggests that by binding to albumin, aldoxorubicin may allow doxorubicin to cross the blood-brain barrier and into the malignancy. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 20, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 18, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe